gender-affirming hormone therapy

DRUG3 trials

Sponsors

Central Hospital, Nancy, France, Medical University of Vienna, Chulalongkorn University

Conditions

Gender DysphoriaHeadacheHormone Therapy Induced Morphologic ChangeMigraine

Unknown Phase

Metabolic Consequences of Cross-sex Hormonal Treatment

Central Hospital, Nancy, FranceGender Dysphoria

Start: 2020-07-24End: 2021-12-01Target: 98Updated: 2020-08-11

Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

RecruitingNCT06291675

Medical University of ViennaGender Dysphoria, Hormone Therapy Induced Morphologic Change

Start: 2023-03-03End: 2033-03-03Target: 50Updated: 2025-09-26

Headache and Hormone Use Among Transgender Population in Thailand: A Cross-Sectional Online Study

Not yet recruitingNCT07817446

Chulalongkorn UniversityHeadache, Migraine

Start: 2026-11-01End: 2027-12-31Target: 500Updated: 2026-09-14

Related Papers

Increase in visceral adipose tissue and altered metabolic profile in transgender men but not in transgender women one year after starting gender-affirming hormonal therapy.

2025-06-10